Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
AU2012213940A1
Pharmaceutical formulations of HDAC inhibitors
AU2012202000A1
Combination therapies using HDAC inhibitors
CA2700173A1
Methods of synthesis of certain hydroxamic acid compounds
EP1957056A2
Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
CN101189003A
Pharmaceutical formulations of HDAC inhibitors
CA2596405A1
Assays for agents with selective cytotoxicty to hdac resistant cell lines
EP2522396A1
Combination therapies using HDAC inhibitors
AU2004215624A1
Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
EP1583736A1
Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
WO2004064711A2
Modulation of deubiquitinase family members
BR0308908A
Compound, composition, use of a compound, and methods for inhibiting hdac in a cell for the treatment of an hdac-mediated condition, a proliferative condition, cancer, and psoriasis
NZ535065A
Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
NZ525439A
Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
